News

Rafael Medical Technologies, a developer of intravascular devices, has received marketing clearance from FDA for its SafeFlo vena cava filter. The clearance is for the permanent implantation of

US-based Competitive Technologies has reported that its bone nanoparticle biomaterial technology has been issued a third patent supporting the first two patents and providing additional claims regarding the

Belgium-based biopharmaceutical company UCB has received FDA approval for Cimzia, the only PEGylated anti-tumor necrosis factor, for the treatment of adult patients with moderately to severely active rheumatoid

AxioMed Spine has received CE Mark approval for its Freedom lumbar disc, an elastomeric total spinal disc replacement device. The CE Mark approval was received from the notified

Canada-based Oncolytics Biotech has successfully completed patient enrollment in its multi-centre Phase II clinical trial to evaluate the intravenous administration of Reolysin in patients with various sarcomas that

The National Heart, Lung, and Blood Institute of the National Institutes of Health has stopped enrollment into a clinical trial testing the effects of highly concentrated saline solutions

NovImmune, a Switzerland-based biotechnology company, has raised $54.8m to take back control of its lead compounds, NI-0401 and NI-0501, a fully human monoclonal antibody to CD3 and interferon-gamma,

Schering-Plough has initiated patient enrollment in RED-CABG, the Phase III trial for acadesine, an investigational adenosine regulating agent. Acadesine was licensed from PeriCor Therapeutics, a specialty biopharmaceutical company.

FY2009 Outlook AMDL reaffirms that it is on track with its FY2009 projections and expects to meet its FY2009 financial guidance of estimated gross revenues of $64 –